Nonurothelial cancer of the bladder.

H. Abol‐enein,B. Kava,A. Carmack

DOI: https://doi.org/10.1016/J.UROLOGY.2006.08.1107

IF: 2.633

Urology

Abstract:

What problem does this paper attempt to address?

JAK/STAT Signaling is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-Specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B

Yuejiao Dong,Xuefen Li,Yanying Yu,Feifei Lv,Yu Chen

DOI: https://doi.org/10.1016/j.lfs.2020.117663

IF: 6.78

2020-01-01

Life Sciences

Abstract:Aims: Interleukin-35 (IL-35) is a new member of the interleukin-12 family and is composed of the P35 and EB virus-inducible gene 3 subunits. The aims of this study were to examine the roles of IL-35 in the exhaustion of HBV-specific CTLs, as little as known on the subject. Main methods: The relative levels of serum HBV markers were detected using automated biochemical techniques. The HBV DNA copies were measured by RT-qPCR. The expression of inhibitory receptors and the cell cytokines on the surface of CTLs were determined by flow cytometry. The pSTAT1-pSTAT4 protein levels expression was determined by flow cytometry, confocal microscopy and Western blot. Key findings: Our results showed that IL-35 can activate the Janus kinase 1 (JAK1)/tyrosine kinase 2 (TYK2)/ signal transducer and activator of transcription 1 (STAT1)/STAT4 pathway in CTLs in vitro. Interferon-gamma and tumor necrosis alpha-a expression increased in CTLs in the presence of a JAK/STAT-pathway blocker. In addition, we evaluated the expression of the exhaustion-associated molecules programmed death-1, cytotoxic T lymphocyte-associated protein-4, and lymphocyte activation gene-3 in CTLs after adding the JAK-STAT inhibitor The results showed that the expression of exhaustion-associated molecules on the CTL surface decreased after blocking the JAK-STAT pathway. IL-35 inhibited the function of HBV-specific CTLs through the JAK1/TYK2/STAT1/STAT4 pathway, and the function of CTLs was recovered after blocking the JAK/STAT pathway. Significance: These data provide a new experimental basis for immunotherapy for chronic hepatitis B.
Role of Interleukin-21 in HBV Infection: Friend or Foe?

Yongyin Li,Libo Tang,Jinlin Hou

DOI: https://doi.org/10.1038/cmi.2014.109

2014-01-01

Abstract:Interleukin (IL)-21, a cytokine produced by activated CD4(+) T cells, has broad pleiotropic actions that affect the functions of a variety of lymphoid cells. The roles of IL-21 in modulating immunity to infections are currently being defined. Notably, IL-21-mediated cellular and humoral immune responses play an important role in determining the outcome of viral infection. This article reviews the current knowledge on the critical role of IL-21 in hepatitis B virus (HBV) infection. As a competent intermediary, IL-21 derived from virus-specific CD4(+) T cells plays key roles in sustaining CD8(+) T cells and promoting B-cell responses that are essential for effective viral control. However, as a mediator of inflammation, IL-21 is also involved in the development of HBV-induced liver cirrhosis and exacerbating liver injury. Overall, the current data point to IL-21 as an immunomodulatory cytokine in HBV infection. Immunotherapeutic strategies aimed at optimizing the beneficial effects of IL-21 in HBV infection may prove to be a rigorous challenge in the future, as they should foster the strengths of IL-21 while circumventing potential drawbacks.
Interleukin 21 Reinvigorates The Antiviral Activity Of Hepatitis B Virus (Hbv)-Specific Cd8(+) T Cells In Chronic Hbv Infection

Libo Tang,Chengcong Chen,Xueping Gao,Wanyue Zhang,Xin Yan,Yang Zhou,Ling Guo,Xinchun Zheng,Weibin Wang,Fuqiang Yang,Guangze Liu,Jian Sun,Jinlin Hou,Yongyin Li

DOI: https://doi.org/10.1093/infdis/jiy576

2019-01-01

Abstract:Background Strategies that target functional recovery of exhausted hepatitis B virus (HBV)-specific CD8(+) T cells are beneficial for viral control, but the potential for interleukin 21 (IL-21) to rescue CD8(+) T-cell function is not well understood.Methods We investigated the effect of IL-21 on CD8(+) T-cell responses by phenotypic and functional analysis of samples from patients with chronic HBV infection and a mouse model with HBV expression.Results IL-21 promoted the proliferative capacity of HBV-specific CD8(+) T cells and down-regulated expression of the inhibitory receptors programmed death 1 and T-cell immunoglobulin domain and mucin domain 3. Additionally, IL-21 boosted the production of interferon-, granzyme B, and CD107a in HBV-specific CD8(+) T cells and enhanced the cytolytic activity of CD8(+) T cells against HepG2.2.15 cells. Notably, an HBV mouse model established from IL-21 receptor knockout mice showed significantly decreased frequency of HBV-specific CD8(+) T cells and increased levels of serum hepatitis B surface antigen (HBsAg). Meanwhile, administration of recombinant mouse IL-21 in an HBV mouse model established from wild-type mice resulted in enhanced functionality of HBV-specific CD8(+) T cells and accelerated HBsAg clearance.Conclusions IL-21 enhances the antiviral effect of HBV-specific CD8(+) T cells, suggesting that it may contribute to viral clearance in chronic HBV infection.Interleukin-21 is highly expressed in chronic hepatitis B patients with favorable treatment response, and it can reinvigorate antiviral activity of hepatitis B virus (HBV)-specific CD8(+) T cells by down-regulating expression of inhibitory receptors and boosting production of antiviral cytokines.
IL-35 Inhibits HBV Antigen-Specific IFN-γ-producing CTLsin Vitro

Xuefen Li,Li Tian,Yuejiao Dong,Qiaoyun Zhu,Yiyin Wang,Wenzheng Han,Xia Liu,Qin Ni,Yu Chen,Lanjuan Li

DOI: https://doi.org/10.1042/cs20140511

2015-01-01

Clinical Science

Abstract:Interleukin (IL)-35 is an inhibitory cytokine consisting of IL-12A and Epstein-Barr virus-induced gene 3 (Ebi3) and is required by regulatory T-cells (Tregs) for maximal activity. During chronic hepatitis B virus (HBV) infection, Tregs have immunosuppressive effects on HBV-specific T helper (Th) cells, yet little is known about the complex regulation of Tregs and their contribution to the inadequate immune system response to the virus. In the present study, we investigated whether IL-35 is involved in HBV-related cellular immune responses. Cluster of differentiation (CD)4(+) T-cells from peripheral blood were derived from healthy volunteers, resolved HBV individuals and chronic active hepatitis B patients and stimulated with CD3/28-conjugated beads. We analysed mRNA and protein levels of IL-35 and assessed the inhibitory effect of IL-35 on HBV core antigen-specific cytotoxic T lymphocytes (CTLs), dendritic cells (DCs) and effector T-cells (Teffs). Correlation analyses between liver inflammation and HBV DNA load were conducted. Results show that chronic HBV patients harbour significantly higher levels of Ebi3 mRNA and protein in CD4(+) T-cells compared with healthy volunteers and resolved HBV individuals. IL-35 suppressed the proliferation of HBV antigen-specific CTLs and interferon (IFN)-gamma production in vitro. Ex vivo, IL-35 decreased the proliferation of CD4(+)CD45RA(+) naive T-cells, especially in CD4(+)CD25(-)CD45RA(+) naive Teffs. IL-35 inhibited the expansion of CD11c(+) DCs. Our data indicate that IL-35 is highly expressed in chronic HBV CD4(+) T-cells and plays an important role in the inhibition of the cellular immune response in chronic HBV.
Elevated Interleukin-35 Suppresses Liver Inflammation by Regulation of T Helper 17 Cells in Acute Hepatitis B Virus Infection

Deng-Ke Teng,Yi Liu,Yi-Fei Lv,Li Wang,Wei Zhang,Jiu-Ping Wang,Yu Li

DOI: https://doi.org/10.1016/j.intimp.2019.02.048

IF: 5.714

2019-01-01

International Immunopharmacology

Abstract:Interleukin (IL)-35 is a responsive anti-inflammatory cytokine implicated in different diseases processes. It has been reported that elevated IL-35 contributed to immunosuppression in chronic hepatitis by modulation of T helper 17 (Th17) and regulatory T cells. However, the role of IL-35 in acute hepatitis B (AHB) was still not completely elucidated. Thus, in the present study, we analyzed the expression and regulatory activity of IL-35 to Th17 cells and inflammatory response during acute hepatitis B virus (HBV) infection in both peripheral blood cells isolated from AHB patients and in hydrodynamic induced HBV-infected mouse model. Plasma IL-35 level and circulating HBV peptides-induced Th17 frequency was significantly elevated in AHB patients, and IL-35 expression negatively correlated with liver inflammation. In vitro IL-35 stimulation to CD4+ T cells purified from AHB patients down-regulated HBV peptides-induced Th17-phenotype, which presented as reduced IL-17 and IL-22 production. In vivo IL-35 administration dampened liver inflammation in HBV plasmid injected mice, however, did not affect HBV antigens production. This process was accompanied by suppression of natural killer cells and down-regulation of HBV peptides-induced Th17 cells in the liver, but did not affect total intrahepatic lymphocytes and other cell subsets numbers or chemokines expression in the liver. In conclusion, the current data indicated that IL-35 might be a novel mediator associated with hepatocytes damage and liver inflammation by regulating HBV peptides-induced Th17 cells during acute HBV infection. The potential anti-inflammatory property of IL-35 might be pivotal for developing new therapeutic approaches for hepatitis B.
Cytokines and Chemokines in HBV Infection

Shihong Zhong,Tianling Zhang,Libo Tang,Yongyin Li

DOI: https://doi.org/10.3389/fmolb.2021.805625

IF: 6.113

2021-01-01

Frontiers in Molecular Biosciences

Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.
IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

Xuefen Li,Xia Liu,Weilin Wang

DOI: https://doi.org/10.3389/fcell.2021.614847

IF: 5.5

2021-01-01

Frontiers in Cell and Developmental Biology

Abstract:Chronic hepatitis B virus (HBV) infection is a risk factor for liver cirrhosis (LC) and hepatocellular carcinoma (HCC), however, little is known about the mechanisms involved in the progression of HBV-related diseases. It has been well acknowledged that host immune response was closely related to the clinical outcomes of patients with HBV infection. As the factors closely related to the immunomodulatory process, cytokines are crucial in the cell-cell communication and the host responses to HBV infection. Recently, a newly discovered cytokine, designated as interleukin-35 (IL-35), has been proved to be essential for the progression of chronic HBV infection, the development of cirrhosis, the transformation of cirrhosis to HCC, and the metastasis of HCC. Specifically, it showed various biological activities such as inhibiting the HBV-specific cytotoxic T lymphocyte (CTL) proliferation and cytotoxicity, deactivating the immature effector T-cells (Teffs), as well as delaying the proliferation of dendritic cells. It regulated the immune responses by acting as a "brake" on the activation of Teffs, which subsequently played important roles in the pathogenesis of various inflammatory diseases and malignancies. In this review, we focused on the most recent data on the relationship between IL-35 and chronic HBV infection, LC and HCC.
Interleukin-33 Mediates Both Immune-Related and Non-Immune-related Inhibitory Effects Against Hepatitis B Virus

Zixiang Gao,Zhongliang Shen,Jingwen Wu,Yingying Song,Nannan Liu,Qiang Deng,Youhua Xie,Jing Liu

DOI: https://doi.org/10.1016/j.antiviral.2022.105404

IF: 7.6

2022-01-01

Antiviral Research

Abstract:Chronic infection by hepatitis B virus (HBV) is associated with high risks of liver fibrosis, cirrhosis and hepa-tocellular carcinoma. HBV covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocyte serves as transcription template. Neither natural resolution of acute infection nor current treatment options for chronic infection are believed to cause cccDNA clearance. We previously showed that injection of IL-33-expressing plasmid facilitated clearance of intrahepatic HBV DNA in a mouse model of HBV persistence. In this work, HBV-targeting therapeutic effects of IL-33 were further explored. Murine IL-33 delivered by recombinant adeno-associated virus (AAV-mIL-33) induced clearance of both serum HBV markers and intrahepatic HBV DNA in two mouse models of HBV persistence based on replicon plasmid and recombinant cccDNA (rcccDNA) respectively. Clearance was associated with serum ALT elevations and liver infiltrations by CD4+ and CD8+ T cells, indicating IL-33-induced cellular immune responses against HBV-harboring cells. Adoptive transfer of splenocytes from AAV-mIL-33-cured mice was indeed sufficient to engender similar clearance in recipient mice. In vitro, intra-cellular, instead of extracellular, IL-33 was mainly responsible for repressing viral transcription, protein pro-duction and genome replication in Huh7 cells transfected with HBV replicon or rcccDNA. IL-33 was shown to be recruited onto rcccDNA minichromosome accompanied by loss of transcriptional activation epigenetic marks. Finally, transfection of IL-33 into HBV-infected HepG2/NTCP cells resulted in reduced transcription, antigen expression and genome replication, suggesting repression of canonical cccDNA. These data demonstrated diverse inhibitory effects on HBV and HBV-infected cells mediated by IL-33, and suggest IL-33 as an interesting thera-peutic candidate.
High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

Shi-Wu Ma,Xuan Huang,Yong-Yin Li,Li-Bo Tang,Xiao-Feng Sun,Xiao-Tao Jiang,Yue-Xin Zhang,Jian Sun,Zhi-Hua Liu,William G H Abbott,Yu-Hong Dong,Nikolai V Naoumov,Jin-Lin Hou

DOI: https://doi.org/10.1016/j.jhep.2011.10.020

IF: 25.7

2012-01-01

Journal of Hepatology

Abstract:Interleukin-21 (IL-21) stimulates T cell and B cell responses and plays a role in control of chronic viral infections. The role of IL-21 in chronic hepatitis B virus (HBV) infection is not understood.Serum IL-21 levels were measured by enzyme immunoassay in 75 HBeAg-positive chronic hepatitis B (CHB) patients undergoing telbivudine treatment. The findings were validated in 103 patients from a separate clinical trial of telbivudine. A complete response to telbivudine was defined as having both HBeAg seroconversion and serum HBV-DNA level <300 copies/ml by treatment week 52. The proportions of T-cells producing IL-21 and/or expressing programmed death 1 (PD-1) in peripheral blood mononuclear cells were assessed longitudinally during treatment by intracellular cytokine staining and flow cytometry.Median serum IL-21 levels at treatment week 12 were significantly higher in patients who did achieve vs. patients who did not achieve a complete response in both the initial (128.4 vs. 69.2 pg/ml, p=0.003) and the validation (142.2 vs. 89.9 pg/ml, p=0.004) trials. Serum levels of IL-21 (p=0.005) or HBV-DNA (p=0.003) levels at treatment week 12 independently predicted HBeAg seroconversion in the first year of treatment. The decrease in PD-1 expression on CD4(+) and CD8(+) T cells during the first 12 weeks on telbivudine treatment was not correlated with changes in IL-21 concentrations.Serum IL-21 levels may be a biomarker for HBeAg seroconversion, and may contribute to individualization of antiviral therapy in HBeAg-positive CHB. IL-21 may also have a role in immunotherapy for CHB.
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).

Joseph Armstrong Martin,D. Bushnell,I. Duncan,S. J. Dunsdon,M. Hall,P. Machin,J. H. Merrett,K. Parkes,NA Roberts,G. Thomas,S. A. Galpin,D. Kinchington

DOI: https://doi.org/10.1002/CHIN.199104325

IF: 8.039

1990-08-01

Journal of Medicinal Chemistry

Abstract:A range of 2'-fluoro and 2',3'-difluoro analogues of pyrimidine deoxyribonucleosides have been synthesized and evaluated against human immunodeficiency virus (HIV-1) in a human lymphoblastoid cell line. Among these compounds, 1-(2,3-dideoxy-2-fluoro-beta-D-threopentofuranosyl)cytosine (12), 2',3'-didehydro-2',3'-dideoxy-2'-fluorocytidine (35), 1-(2,3-dideoxy-2,3-difluoro-beta-D-arabinofuranosyl)cytosine (41), and 3'-deoxy-2',3'-didehydro-2'-fluorothymidine (45) were found to have significant antiviral activity, with IC50 values of 0.65, 10, 10, and 100 microM, respectively. The structure-activity relationships are discussed.
The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.

Chengbo Yu,Xianli Gong,Qian Yang,Jiangshan Lian,Kaijin Xu,Bin Ruan,Lanjuan Li

DOI: https://doi.org/10.1111/liv.12701

IF: 8.754

2015-01-01

Liver International

Abstract:Background & AimsThis study investigated the possible use of interleukin (IL)-23 and IL-17 serum levels as indicators for anti-hepatitis B virus (HBV) therapy. MethodsA total of 127 patients with chronic hepatitis B (CHB) who received pegylated interferon (PegIFN) therapy, 20 chronic asymptomatic HBV carriers (AsCs) and 32 healthy controls were recruited. The serum levels of IL-23 and IL-17 were detected by ELISA. The predictive value of baseline and early on-treatment changes in the levels of IL-23 and IL-17 for therapeutic response were evaluated by receiver operating characteristic analysis. Multivariate logistic regression models were generated to identify independent factors that affect the clearance of hepatitis B e antigen (HBeAg) and the decline in hepatitis B surface antigen (HBsAg). ResultsThe baseline serum levels of IL-23 and IL-17 were higher in patients with CHB than in normal controls and in AsCs. High levels of pre-treatment IL-23 and IL-17 and more significant on-treatment reductions in IL-23 and IL-17 levels were observed in patients with CHB who achieved HBeAg clearance or a decline in HBsAg >1log(10)IU/ml compared with patients who were persistently HBeAg-positive or who experienced a decline in HBsAg <1log(10)IU/ml. The predictive cut-off value of IL-23 for HBeAg clearance was 135pg/ml, and the specificity and sensitivity were 71.4% and 70% respectively. A high pre-treatment level of IL-23 was an independent factor for the prediction of the therapeutic response in patients with HBeAg-positive CHB. Early on-treatment changes of IL-23 and IL-17 showed no predictive value. ConclusionsA high pre-treatment serum IL-23 level predicts the therapeutic response in HBeAg-positive CHB patients during PegIFN therapy.
The Mechanism of Interleukin-35 in Chronic Hepatitis B

Ying Tang,Tianyi Ma,Shengnan Jia,Qian Zhang,Siqi Liu,Ling Qi,Lanlan Yang

DOI: https://doi.org/10.1055/s-0041-1731708

2021-07-07

Seminars in Liver Disease

Abstract:Abstract Interleukin-35 (IL-35) is a newly identified inhibitory cytokine. It has recently been found to play an extremely important role in chronic hepatitis B disease, which makes it likely to be a target for new therapies for hepatitis B malady. IL-35 modulates a variety of immune mechanisms to cause persistent viral infections, such as affecting the ratio of helper T cells, reducing the activity of cytotoxic T cells, hindering the antigen presentation capacity for dendritic cells, and increasing the transcription level of hepatitis B virus. On the other hand, IL-35 can control the inflammation caused by hepatitis B liver injury. Therefore, to seek a breakthrough in curing hepatitis B disease, the contradictory part of IL-35 in the occurrence and development of this sickness is worthy of further discussion and research. This article will systematically review the biological effects of IL-35 and the specific mechanisms affecting the disease.

gastroenterology & hepatology
Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

ZHAO Xue-hui,YANG Jie-zuan,WEI Li,HU Yun-liang,LI Lan-juan

2010-01-01

Abstract:Objective:To observe the levels of interleukin-18(IL-18),interferon-inducible protein-10(IP-10) in plasma of patients with chronic hepatitis B(CHB) in the process of antiviral treatment,and further analysis its clinical significance.Methods:Plasma levels of IL-18,IP-10 in 33 patients with CHB at different antiviral stages were determined by double antibody sandwich ELISA,and their biochemical indicator of liver function was determined at the same time.Results:Levels of both IL-18 and IP-10 in the 12th and 24th week after antiviral treatment are lower than that of the prior treatment(P0.05).After antiviral treatment,the levels of IL-18 and IP-10 are positively correlated with alanine transaminase′s(ALT)(r=0.269,0.656,P0.05,P0.01).Conclusion:Both IL-18 and IP-10 in the plasma of patients with CHB may play important roles in immune damage of liver cells.Monitoring plasma levels of IL-18 and IP-10 in the process of antiviral treatment can be used to reveal the immune statue and evaluate the efficacy of antiviral drug.
Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells

Jiaxuan Zhang,Kai Liu,Gaoli Zhang,Ning Ling,Min Chen

DOI: https://doi.org/10.1186/s12985-022-01753-x

IF: 5.916

2022-02-10

Virology Journal

Abstract:Abstract Background Some cytokine signaling pathways can interact with interferon (IFN)-α pathway and thus regulate cell responses to IFN-α. Levels of the pro-inflammatory cytokine interleukin-17A (IL-17A) were found to be elevated in both the peripheral blood and liver in chronic hepatitis B (CHB) patients. However, how IL-17A affects the anti-HBV activity of IFN-α remains unclear. Methods The effects of IL-17A on anti-HBV activity of IFN-α were evaluated in HBV-expressing HepG2 cells (HepG2-HBV1.3) with IL-17A pretreatment and IFN-α stimulation. Culture supernatant levels of HBsAg, HBeAg, and HBV DNA, or intracellular expression of HBsAg and HBcAg were detected by ELISA, real-time quantitative PCR (RT-qPCR), or western blotting (WB). The expression of canonical IFN-α signaling pathway components, including the interferon-α/β receptor (IFNAR), Janus Kinase 1 (JAK1), Tyrosine Kinase 2 (TYK2), the Interferon Stimulated Gene Factor 3 complex (ISGF3) and IFN-stimulated genes (ISGs), was also examined by RT-qPCR, Immunofluorescence or WB. The effects of IL-17A were further investigated by the suppression of the IL-17A pathway with a TRAF6 inhibitor. Results Compared to IFN-α stimulation alone, IL-17A pretreatment followed by IFN-α stimulation increased the levels of HBsAg, HBeAg, and HBV DNA, and decreased the levels of ISGF3 complex (phosphorylated (p)-signal transducer and activator of transcription (STAT1)/p-STAT2/IRF9) and antiviral-related ISGs (ISG15, ISG20 and Mx1). Interestingly, IL-17A pretreatment increased the expression of suppressor of cytokine signaling (SOCS) 1, SOCS3 and USP18, which were also the ISGs negatively regulating activity of ISGF3. Moreover, IFNAR1 protein expression declined more sharply in the group with IL-17A pretreatment than in the group with IFN-α stimulation alone. Blocking the IL-17A pathway reversed the effects of IL-17A on the IFN-α-induced activation of ISGF3 and anti-HBV efficacy. Conclusions Our results demonstrate that IL-17A pretreatment could attenuate IFN-α-induced anti-HBV activity by upregulating negative regulators of the critical transcriptional ISGF3 complex. Thus, this might be a potential target for improving response to IFN-α therapy.

virology
Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Xue-hui ZHAO,Jie-zuan YANG,Yun-liang HU,Hai-feng LU,Li WEI,Bao-hong WANG,Lan-juan LI

DOI: https://doi.org/10.3760/cma.j.issn.1000-6680.2011.11.007

2011-01-01

Abstract:Objective To determine the changes of peripheral levels of T helper cell cytokines of patients with chronic hepatitis B (CHB) during antiviral treatment,and to further explore its clinical significance.Methods The plasma levels of interleukin (IL)-2,IL-6,IL-10,interferon (IFN)-γ and tumor necrosis factor(TNF)-α of thirty-three CHB patients during antiviral treatment (entecavir) were measured using enzyme linked immunosorbont assay (ELISA).And their biochemical indicators of liver function were determined.The differences of cytokines levels before and after antiviral treatment were compared using ANOVA.The correlations between the changes of cytokines and alanine transaminase (ALT),hepatitis B virus (HBV) DNA levels were analyzed.Results Levels of IFNγ before and 12,24,48 weeks after treatment were (5.98±2.77),(5.95±3.37),(2.93±2.15) and (9.29±4.65) pg/mL,respectively (F=3.845,P＜0.05),which were positively correlated with ALT levels (r =0.396,P＜0.05).Both TNF-α and IL-10 levels declined after antiviral treatment,which were significantly different at different time points (F=20.156 and 16.695,respectively; both P＜0.05),and both levels of TNF-α and IL-10 were positively correlated with ALT levels (r=0.354and 0.316,respectively; both P＜0.05) and positively correlated with HBV DNA levels (r=0.382and 0.386,respectively; both P＜0.05).While both IL-2 and IL-6 levels were not significantly different between before and after antiviral treatment (F=0.010 and 0.932,respectively; both P＞0.05).The serum levels of ALT and HBV DNA before and after antiviral treatment were all significantly different (F=17.69 and 198.98,respectively; both P＜0.05),which declined gradually during treatment and were positively correlated (r =0.581,P＜0.05).Conclusions IL-10,IFNγand TNF-α may be involved in the pathologic process of CHB,and closely related to the deterioration of the disease.Monitoring plasma levels of these cytokines during antiviral treatment could be useful to understand the immune status and evaluate the efficacy of antiviral drugs.
In Vitro Immunomodulatory Activity of Interferon Alpha on Toll-Like Receptor 9 Signaling Pathway in Chronic Hepatitis B

Xin Wang,Ying-Ren Zhao,Hong-Li Liu,Xiao-Hua Ma,Yu Zhang

DOI: https://doi.org/10.1089/jir.2014.0182

2015-01-01

Abstract:Interferon alpha (IFN-α) is registered for chronic hepatitis B (CHB) treatment. However, the antiviral mechanism of IFN-α and the biological function of many IFN-α responsive genes have not been fully elucidated. We investigated to determine the regulative effect of IFN-α on toll-like receptor (TLR) 9 signaling in peripheral blood mononuclear cells (PBMCs) from CHB patients in vitro. We examined the changes of expression and function of TLR9 signaling pathway in the PBMCs with different treatment methods and investigated the synergism of IFN-α and TLR9 ligand on antiviral cytokine secretions in vitro. The data showed that, for the TLR9 signaling pathway, IFN-α not only augmented the expressions of TLR9 signal transduction molecules but also activated the TLR9 signal function. This study has clearly demonstrated that the TLR9 ligand could stimulate PBMCs that have been pretreated with IFN-α. Furthermore, the quantity of antiviral cytokines secreted by the pretreated PBMCs was greater than those without pretreatment. The interaction between IFN-α and TLR9 ligand appears to be synergistic. Data revealed IFN-α could influence TLR9 signaling transduction and synergistically improve the immune efficacy of TLR9 ligand against CHB. The present study suggests a potential novel mechanism for the antiviral activity against hepatitis B virus and a new individualized antiviral strategy.
INTERLEUKIN-33 INHIBITS HEPATITIS B VIRUS REPLICATION IN THE LIVERS OF TRANSGENIC MICE

Y. -F. Jiang,D. -M. Xu,W. -Y. Li,J. -Q. Niu

DOI: https://doi.org/10.1016/S0168-8278(10)60623-X

IF: 25.7

2010-01-01

Journal of Hepatology

Abstract:examined at every 12 weeks treatment for serum HBV DNA loads, alanine transaminase (ALT) and aspartate transaminase (AST) levels.Phenotypes of peripheral blood lymphocyte subsets (T cells, CD3 -CD56 + NK cells, CD3 + CD56 + NKT cells, CD4 + CD25 + FoxP3 + Treg cells and 2B4 + CD56 + cells) were analysed using flow cytometry.Results: The results showed significantly reduced numbers of CD3 -CD56 + NK cells with CHB patients (p = 0.013), while the proportion of CD3 + CD4 + T cells, Treg cells and the ratio of CD4/CD8 were significantly higher than that of healthy controls (p = 0.025, p = 0.006 and p = 0.046).The expression of receptor 2B4 + on CD3 -CD56 + NK cells were lower in CHB patients compared to that in healthy controls (p = 0.021).The CD3 -CD56 + NK and 2B4+ expression on natural killer cells in post-treatment group were increased than that in pre-treatment group(p = 0.001).A significant inverse correlation was obtained between 2B4 + CD56 + NK cells and HBV DNA levels (R = 0.278, p = 0.035).Conclusions: These findings demonstrate that the concentration of 2B4 + CD56 + NK cells normalizes with LDT treatment in CHB patients.The finding that HBV was associated negatively with the concentration of 2B4 + CD56 + NK cells suggests that immune activation in CHB patients receiving LDT influences the target cell recognition by NK cells.
Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma

Qian Zhang,Lanlan Yang,Siqi Liu,Mengyao Zhang,Zhenjing Jin

DOI: https://doi.org/10.3389/fimmu.2021.645835

IF: 7.3

2021-06-10

Frontiers in Immunology

Abstract:Chronic hepatitis B virus (HBV) infection induces dysfunction of immune response and chronic liver damage. However, the mechanisms that account for HBV-related hepatocellular carcinoma (HCC) are poorly understood. The aim of present study was to investigate the modulatory role of interleukin (IL)-35, an immunosuppressive cytokine, to IL-9-secreting T cells in hepatitis B-related HCC. Twenty-two HBV-related HCC patients, twenty-seven chronic hepatitis B (CHB) patients, and eleven controls were enrolled. Serum IL-35 and IL-9 concentration was measured by ELISA. Peripheral and liver-infiltrating non-specific and HBV-specific Th9 and Tc9 cells were assessed by flow cytometry. The regulatory activity of IL-35 to peripheral and liver-infiltrating Th9 cells was assessed in co-culture system between CD8 + T cells and HepG2.2.15 cells. Serum IL-35 was up-regulated, while IL-9 was down-regulated in HBV-related HCC patients compared with in CHB patients and controls. Peripheral non-specific and HBV-specific Th9 cells, but not Tc9 cells, were decreased in HBV-related HCC patients. Liver-infiltrating non-specific and HBV-specific Th9 cells were also reduced in HCC tumor sites. CD8 + T cells from CHB and HBV-related HCC patients revealed decreased cytotoxicity compared with those from controls. Autologous Th9 cells mediated the elevation of CD8 + T cell cytotoxicity, and this process was depending on IL-9 secretion. Recombinant IL-35 stimulation inhibited IL-9 secretion and PU.1 mRNA expression in non-specific and HBV-specific Th9 cells, leading to the suppression of Th9-mediated CD8 + T cell cytotoxicity in CHB and HBV-related HCC patients. Our current data indicated that IL-35 might dampen non-specific and HBV-specific Th9 cells activity in HBV-related HCC patients.

immunology
Increased Interleukin-32 Expression in Chronic Hepatitis B Virus-Infected Liver

Qihuan Xu,Xingfei Pan,Xin Shu,Hong Cao,Xuejun Li,Ka Zhang,Jianxi Lu,Yong Zou,Xueling Li,Hongcan Liu,Yeqiong Zhang,Daofeng Yang,Qin Ning,Guanxin Shen,Gang Li

DOI: https://doi.org/10.1016/j.jinf.2012.05.009

IF: 28.2

2012-01-01

Journal of Infection

Abstract:OBJECTIVES:The role of interleukin-32 (IL-32) in chronic hepatitis B (CHB) remains unclear. In order to identify the role of IL-32 in CHB, we detected the expression levels of IL-32 in liver samples of CHB patients and analyzed the correlation between IL-32 and liver inflammation/fibrosis.METHODS:Real-time PCR and immunohistochemistry were used to detect the expression levels of IL-32 in liver tissues of patients with CHB. The correlation between hepatic IL-32 expression and the severity of liver inflammation/fibrosis was assessed using Spearman's correlation.RESULTS:Hepatic IL-32 expression was increased in CHB patients and increased with the severity of liver inflammation/fibrosis. Moreover, hepatic IL-32 expression was significantly positively correlated with serum ALT level and negatively related with serum ALB level.CONCLUSIONS:Our results suggest that IL-32 could be implicated in HBV-related liver inflammation/fibrosis. We believe that IL-32 might play important roles in the pathogenesis of CHB.
IL-22-producing CD3 + CD8- T cells increase in immune clearance stage of chronic HBV infection and correlate with the response of Peg-interferon treatment

Li-Yuan Wang,Xue-Yan Yang,Yin-Ping Wu,Yu-Chen Fan

DOI: https://doi.org/10.1016/j.clim.2023.109320

IF: 10.19

2023-05-01

Clinical Immunology

Abstract:Interleukin (IL)-22 regulates host defense. This study investigated the predominant IL-22-producing cell subsets under HBV associated immune stages. We found circulating IL-22-producing CD3 + CD8- T cells were significantly increased in immune active (IA) stage than those in immunotolerant stage, inactive carrier and healthy controls (HCs). The plasma IL-22 level was higher in IA and HBeAg-negative CHB compared to HCs. Importantly, CD3 + CD8- T cells were identified as the predominant source of plasma IL-22 production. Up-regulated IL-22-producing CD3 + CD8- T cells obviously correlated with the grade of intrahepatic inflammation. The proportions of IL-22-producing CD3 + CD8- T cells were significantly down-regulated after 48 weeks of Peg-interferon treatment, and the differences were of great significance in patients with normalize ALT levels at 48 weeks, rather than those with elevated ALT levels. In conclusion, IL-22 might play a proinflammatory function in. chronic HBV infected patients with active inflammation and Peg-interferon treatment could attenuate the degree of liver inflammation through down-regulating IL-22-producing CD3 + CD8- T cells.

immunology

Nonurothelial cancer of the bladder.

JAK/STAT Signaling is Involved in IL-35-induced Inhibition of Hepatitis B Virus Antigen-Specific Cytotoxic T Cell Exhaustion in Chronic Hepatitis B

Role of Interleukin-21 in HBV Infection: Friend or Foe?

Interleukin 21 Reinvigorates The Antiviral Activity Of Hepatitis B Virus (Hbv)-Specific Cd8(+) T Cells In Chronic Hbv Infection

IL-35 Inhibits HBV Antigen-Specific IFN-γ-producing CTLsin Vitro

Elevated Interleukin-35 Suppresses Liver Inflammation by Regulation of T Helper 17 Cells in Acute Hepatitis B Virus Infection

Cytokines and Chemokines in HBV Infection

IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases.

Interleukin-33 Mediates Both Immune-Related and Non-Immune-related Inhibitory Effects Against Hepatitis B Virus

High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.

Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).

The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.

The Mechanism of Interleukin-35 in Chronic Hepatitis B

Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

In Vitro Immunomodulatory Activity of Interferon Alpha on Toll-Like Receptor 9 Signaling Pathway in Chronic Hepatitis B

INTERLEUKIN-33 INHIBITS HEPATITIS B VIRUS REPLICATION IN THE LIVERS OF TRANSGENIC MICE

Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma

Increased Interleukin-32 Expression in Chronic Hepatitis B Virus-Infected Liver

IL-22-producing CD3 + CD8- T cells increase in immune clearance stage of chronic HBV infection and correlate with the response of Peg-interferon treatment